Reader response: Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

Hawkins and Berman1 acknowledge limitations to current therapeutic approaches (including medication costs), but underestimate potential negative effects of Parkinson disease psychosis (PDP) on the patient, caregiver, and health care system. PDP may be a harbinger of increased risk of morbidity and mortality, as well as portend admittance to a long-term care facility; these factors ultimately correlate with a surmountable burden on the system and higher cost to the patient over time